These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Rationale and design of MANJUSRI trial: a randomized, open-label, active-controlled multicenter study to evaluate the safety of combined therapy with ticagrelor and warfarin in AF subjects after PCI-eS. Lu W; Chen L; Wang Y; Yao Y; Fu C; Zuo P; Ma G Contemp Clin Trials; 2015 Jan; 40():166-71. PubMed ID: 25513965 [TBL] [Abstract][Full Text] [Related]
9. Risk and Benefits of Triple Therapy in Patients Undergoing Coronary Stent Implantation Requiring Oral Anticoagulation: A Meta-Analysis of 16 Studies. Barbieri L; Verdoia M; Schaffer A; Suryapranata H; De Luca G Cardiovasc Drugs Ther; 2016 Dec; 30(6):611-622. PubMed ID: 27757726 [TBL] [Abstract][Full Text] [Related]
10. Rationale and design of The Intracoronary Stenting and Antithrombotic Regimen-Testing of a six-week versus a six-month clopidogrel treatment Regimen In Patients with concomitant aspirin and oraL anticoagulant therapy following drug-Eluting stenting (ISAR-TRIPLE) study. Fiedler KA; Byrne RA; Schulz S; Sibbing D; Mehilli J; Ibrahim T; Maeng M; Laugwitz KL; Kastrati A; Sarafoff N Am Heart J; 2014 Apr; 167(4):459-465.e1. PubMed ID: 24655693 [TBL] [Abstract][Full Text] [Related]
11. Drug insight: antithrombotic therapy after percutaneous coronary intervention in patients with an indication for anticoagulation. Helft G; Gilard M; Le Feuvre C; Zaman AG Nat Clin Pract Cardiovasc Med; 2006 Dec; 3(12):673-80. PubMed ID: 17122800 [TBL] [Abstract][Full Text] [Related]
12. Bleeding risk with triple antithrombotic therapy in patients with atrial fibrillation and drug-eluting stents. Enomoto Y; Iijima R; Tokue M; Ito N; Nagashima Y; Araki T; Yamazaki K; Utsunomiya M; Hori M; Itaya H; Shiba M; Hara H; Nakamura M; Sugi K Cardiovasc Interv Ther; 2014 Jul; 29(3):193-9. PubMed ID: 24366503 [TBL] [Abstract][Full Text] [Related]
13. Efficacy of modified dual antiplatelet therapy combined with warfarin following percutaneous coronary intervention with drug-eluting stents. Baber U; Akhter M; Kothari S; Sharma SK; Kini A J Invasive Cardiol; 2010 Feb; 22(2):80-3. PubMed ID: 20124594 [TBL] [Abstract][Full Text] [Related]
14. Antithrombotic regimens in patients with atrial fibrillation and coronary artery disease after percutaneous coronary intervention: A focused review. Chang KW; Arbit B; Hsu JC Int J Cardiol; 2017 Sep; 243():263-269. PubMed ID: 28595745 [TBL] [Abstract][Full Text] [Related]
15. Antithrombotics in atrial fibrillation and coronary disease. Velagapudi P; Turagam MK; Agrawal H; Mittal M; Kocheril AG; Aggarwal K Expert Rev Cardiovasc Ther; 2014 Aug; 12(8):977-86. PubMed ID: 25046150 [TBL] [Abstract][Full Text] [Related]
16. Anticoagulant and antiplatelet therapy use in patients with atrial fibrillation undergoing percutaneous coronary intervention: the need for consensus and a management guideline. Lip GY; Karpha M Chest; 2006 Dec; 130(6):1823-7. PubMed ID: 17167003 [TBL] [Abstract][Full Text] [Related]
19. [Impact of different antithrombotic therapy strategy on prognosis in coronary heart disease patients combining with atrial fibrillation: a meta analysis]. Yuan C; Zhong L; Huang RC Zhonghua Xin Xue Guan Bing Za Zhi; 2017 Jun; 45(6):526-535. PubMed ID: 28648031 [No Abstract] [Full Text] [Related]
20. Rationale and design of the SAFE-A study: SAFety and Effectiveness trial of Apixaban use in association with dual antiplatelet therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention. Hoshi T; Sato A; Nogami A; Gosho M; Aonuma K; J Cardiol; 2017 Apr; 69(4):648-651. PubMed ID: 27443596 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]